Venus Remedies Limited (VENUSREM) fundamentals
Venus Remedies Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as VENUSREM (ISIN INE411B01019). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Venus Remedies Limited does
Venus Remedies Limited is a research-driven pharmaceutical company. The Company is a global injectable manufacturer. It manufactures products catering to critical care segments such as antimicrobial resistance, anti-cancer, Anti-infective, Neurology, Skin and Wound Care, and Pain Management. With a diverse portfolio of products, the Company is dedicated to revolutionizing patient care through its specialized therapeutic segments such as anti-infective (antibiotics), oncology, neurology, pain management, and skin & wound care. The Company operates only in one business segment: Pharmaceutical Formulation and is engaged in manufacturing and trading of medicines. Its focus therapy areas include medicine, surgery, neuro and orthopedics. The Company’s brands include Potentox, Vancoplus Combi, Tobracef, Supime, Zydotum, Neurotol, Trois, Septiloc, Mucomelt, and others. It has three manufacturing facilities: Panchkula and Baddi in India and Werne in Germany.
Valuation and market data
| Last close | ₹1624.20 |
|---|---|
| Market capitalisation | ₹2,171 crore |
| Enterprise value | ₹2,132 crore |
| P/E (TTM) | 0.00 |
| Price to book | 3.87 |
| Price to sales (TTM) | 2.64 |
| Book value per share | ₹419.68 |
| Dividend yield | 61.57% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Wed Dec 20 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹780 crore | ₹131 crore | ₹99 crore | 0.00 |
| Mar 2025 | ₹660 crore | ₹79 crore | ₹53 crore | 39.32 |
| Mar 2024 | ₹587 crore | ₹47 crore | ₹31 crore | 22.82 |
| Mar 2023 | ₹548 crore | ₹40 crore | ₹29 crore | 21.67 |
| Mar 2022 | ₹585 crore | ₹45 crore | ₹49 crore | 37.12 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 41.8% |
|---|---|
| Foreign institutions (FII) | 2.9% |
| Mutual funds | 0.0% |
| Other domestic institutions | 0.9% |
| Retail and others | 54.4% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.